FCCC LOGO Faculty Publications
Silvers RM , Smith JA , Schowalter M , Litwin S , Liang ZH , Geary K , Daniel R
Modification of Integration Site Preferences of an HIV-1-Based Vector by Expression of a Novel Synthetic Protein
Human Gene Therapy. 2010 Mar;21(3) :337-349
PMCID: PMC2865216   
Back to previous list
Abstract
HIV-1-based lentiviral vectors are a promising tool for gene therapy. However, integration of a lentiviral vector into host cell genes may lead to the development of cancer. Therefore, control of integration site selection is critical to the successful outcome of gene therapy approaches that use these vectors. The discovery that integration site selection by HIV-1 and HIV-1-based vectors is controlled by the LEDGF/p75 protein has presented new opportunities to control integration site selection. In this study, we tested the hypothesis that a fusion protein containing the C-terminal HIV integrase-binding portion of LEDGF/p75, and the N-terminal chromo-domain of heterochromatin protein-1 alpha (HP1 alpha), can target HIV-1 vector DNA outside of genes. We show that this fusion protein, termed TIHPLE, associates with the heterochromatin hallmark trimethylated Lys-9 of histone H3 (H3K9me3). Transient overexpression of TIHPLE alters integration site selection by an HIV-1-based vector and decreases the number of integration events that occur in genes. This change in integration site selection was achieved without a reduction in overall integration efficiency. Furthermore, we show that TIHPLE increases integration in the vicinity of H3K9me3 and in repetitive DNA sequences. These data provide a novel approach to address the problem of the tendency of retroviral vectors to integrate at undesirable sites of the human genome.
Notes
Silvers, Robert M. Smith, Johanna A. Schowalter, Michael Litwin, Samuel Liang, Zhihui Geary, Kyla Daniel, Rene Mary ann liebert inc New rochelle 570lv